A molecular CT blood pool contrast agent

David R. Vera, Robert F. Mattrey

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Rationale and Objectives. A molecular-based computed tomographic (CT) contrast agent with prolonged vascular residence time is needed for vascular and tumor imaging. No particulate agents have reached clinical practice due to nonspecific macrophage activation. The authors' objective was to synthesize a water-]soluble macromolecular agent. Materials and Methods. Dysprosium-DTPA-dextran was synthesized through activation of the hydroxyl units of dextran PM40 with allylbromine and subsequent reaction with amino ethanethiol to produce amino-terminated leashes. These leashes were then coupled to DTPA by means of the mixed anhydride method. Complexation of dysprosium by DTPAdextran was achieved in an acidic solution of 0.2 M dysprosium chloride. One rabbit with a VX2 tumor was imaged with [Dy]DTPA-dextran (0.5 mL, 3.1 g, 1.15 mmol of dysprosium per kilogram). Transaxial scans were acquired through the liver and tumor for 45 minutes. A second healthy rabbit was imaged with Optiray-320 (6.0 mL, 5.0 mmol of iodine per kilogram) at 1-minute intervals for 10 minutes and again at 20 minutes. Results. Each dextran PM40 molecule (diameter, 8.8 nm) contained 95 [Dy]DTPA groups, increasing its average molecular weight from 40,500 to 101,537 g/mol. The baseline-corrected inferior vena cava (IVC) enhancement for [Dy]DTPAdextran decreased, with an 8-minute half-time during the first 15 minutes followed by a nearly zero slope for the rest of the observation period. The IVC remained brighter than liver throughout the observation period. The solid portion of the tumor was enhanced by 5-10 CT numbers, rendering areas of necrosis more apparent. The baseline-corrected IVC curve for Optiray-320 also demonstrated two phases, with half-times of 2.5 and 45 minutes. The IVC became less dense than liver within 5-8 minutes. Conclusion. [Dy]DTPA-dextran is water soluble and can be synthesized without intermolecular cross-linking to carry a high load of dysprosium. It provides blood pool enhancement characteristics with a long intravascular dwell time.

Original languageEnglish (US)
Pages (from-to)784-792
Number of pages9
JournalAcademic Radiology
Volume9
Issue number7
DOIs
StatePublished - Jan 1 2002

Fingerprint

Dysprosium
Dextrans
ioversol
Contrast Media
Inferior Vena Cava
Blood Vessels
Liver
Neoplasms
Observation
Rabbits
Pentetic Acid
Macrophage Activation
Water
Anhydrides
Iodine
Hydroxyl Radical
Chlorides
Necrosis
Molecular Weight
dysprosium DTPA

Keywords

  • Computed tomography (CT), contrast media
  • Computed tomography (CT), vascular studies
  • Dysprosium

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

A molecular CT blood pool contrast agent. / Vera, David R.; Mattrey, Robert F.

In: Academic Radiology, Vol. 9, No. 7, 01.01.2002, p. 784-792.

Research output: Contribution to journalArticle

Vera, David R. ; Mattrey, Robert F. / A molecular CT blood pool contrast agent. In: Academic Radiology. 2002 ; Vol. 9, No. 7. pp. 784-792.
@article{718935ba72b740a49410fb06f89d5b66,
title = "A molecular CT blood pool contrast agent",
abstract = "Rationale and Objectives. A molecular-based computed tomographic (CT) contrast agent with prolonged vascular residence time is needed for vascular and tumor imaging. No particulate agents have reached clinical practice due to nonspecific macrophage activation. The authors' objective was to synthesize a water-]soluble macromolecular agent. Materials and Methods. Dysprosium-DTPA-dextran was synthesized through activation of the hydroxyl units of dextran PM40 with allylbromine and subsequent reaction with amino ethanethiol to produce amino-terminated leashes. These leashes were then coupled to DTPA by means of the mixed anhydride method. Complexation of dysprosium by DTPAdextran was achieved in an acidic solution of 0.2 M dysprosium chloride. One rabbit with a VX2 tumor was imaged with [Dy]DTPA-dextran (0.5 mL, 3.1 g, 1.15 mmol of dysprosium per kilogram). Transaxial scans were acquired through the liver and tumor for 45 minutes. A second healthy rabbit was imaged with Optiray-320 (6.0 mL, 5.0 mmol of iodine per kilogram) at 1-minute intervals for 10 minutes and again at 20 minutes. Results. Each dextran PM40 molecule (diameter, 8.8 nm) contained 95 [Dy]DTPA groups, increasing its average molecular weight from 40,500 to 101,537 g/mol. The baseline-corrected inferior vena cava (IVC) enhancement for [Dy]DTPAdextran decreased, with an 8-minute half-time during the first 15 minutes followed by a nearly zero slope for the rest of the observation period. The IVC remained brighter than liver throughout the observation period. The solid portion of the tumor was enhanced by 5-10 CT numbers, rendering areas of necrosis more apparent. The baseline-corrected IVC curve for Optiray-320 also demonstrated two phases, with half-times of 2.5 and 45 minutes. The IVC became less dense than liver within 5-8 minutes. Conclusion. [Dy]DTPA-dextran is water soluble and can be synthesized without intermolecular cross-linking to carry a high load of dysprosium. It provides blood pool enhancement characteristics with a long intravascular dwell time.",
keywords = "Computed tomography (CT), contrast media, Computed tomography (CT), vascular studies, Dysprosium",
author = "Vera, {David R.} and Mattrey, {Robert F.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1016/S1076-6332(03)80348-3",
language = "English (US)",
volume = "9",
pages = "784--792",
journal = "Academic Radiology",
issn = "1076-6332",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - A molecular CT blood pool contrast agent

AU - Vera, David R.

AU - Mattrey, Robert F.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Rationale and Objectives. A molecular-based computed tomographic (CT) contrast agent with prolonged vascular residence time is needed for vascular and tumor imaging. No particulate agents have reached clinical practice due to nonspecific macrophage activation. The authors' objective was to synthesize a water-]soluble macromolecular agent. Materials and Methods. Dysprosium-DTPA-dextran was synthesized through activation of the hydroxyl units of dextran PM40 with allylbromine and subsequent reaction with amino ethanethiol to produce amino-terminated leashes. These leashes were then coupled to DTPA by means of the mixed anhydride method. Complexation of dysprosium by DTPAdextran was achieved in an acidic solution of 0.2 M dysprosium chloride. One rabbit with a VX2 tumor was imaged with [Dy]DTPA-dextran (0.5 mL, 3.1 g, 1.15 mmol of dysprosium per kilogram). Transaxial scans were acquired through the liver and tumor for 45 minutes. A second healthy rabbit was imaged with Optiray-320 (6.0 mL, 5.0 mmol of iodine per kilogram) at 1-minute intervals for 10 minutes and again at 20 minutes. Results. Each dextran PM40 molecule (diameter, 8.8 nm) contained 95 [Dy]DTPA groups, increasing its average molecular weight from 40,500 to 101,537 g/mol. The baseline-corrected inferior vena cava (IVC) enhancement for [Dy]DTPAdextran decreased, with an 8-minute half-time during the first 15 minutes followed by a nearly zero slope for the rest of the observation period. The IVC remained brighter than liver throughout the observation period. The solid portion of the tumor was enhanced by 5-10 CT numbers, rendering areas of necrosis more apparent. The baseline-corrected IVC curve for Optiray-320 also demonstrated two phases, with half-times of 2.5 and 45 minutes. The IVC became less dense than liver within 5-8 minutes. Conclusion. [Dy]DTPA-dextran is water soluble and can be synthesized without intermolecular cross-linking to carry a high load of dysprosium. It provides blood pool enhancement characteristics with a long intravascular dwell time.

AB - Rationale and Objectives. A molecular-based computed tomographic (CT) contrast agent with prolonged vascular residence time is needed for vascular and tumor imaging. No particulate agents have reached clinical practice due to nonspecific macrophage activation. The authors' objective was to synthesize a water-]soluble macromolecular agent. Materials and Methods. Dysprosium-DTPA-dextran was synthesized through activation of the hydroxyl units of dextran PM40 with allylbromine and subsequent reaction with amino ethanethiol to produce amino-terminated leashes. These leashes were then coupled to DTPA by means of the mixed anhydride method. Complexation of dysprosium by DTPAdextran was achieved in an acidic solution of 0.2 M dysprosium chloride. One rabbit with a VX2 tumor was imaged with [Dy]DTPA-dextran (0.5 mL, 3.1 g, 1.15 mmol of dysprosium per kilogram). Transaxial scans were acquired through the liver and tumor for 45 minutes. A second healthy rabbit was imaged with Optiray-320 (6.0 mL, 5.0 mmol of iodine per kilogram) at 1-minute intervals for 10 minutes and again at 20 minutes. Results. Each dextran PM40 molecule (diameter, 8.8 nm) contained 95 [Dy]DTPA groups, increasing its average molecular weight from 40,500 to 101,537 g/mol. The baseline-corrected inferior vena cava (IVC) enhancement for [Dy]DTPAdextran decreased, with an 8-minute half-time during the first 15 minutes followed by a nearly zero slope for the rest of the observation period. The IVC remained brighter than liver throughout the observation period. The solid portion of the tumor was enhanced by 5-10 CT numbers, rendering areas of necrosis more apparent. The baseline-corrected IVC curve for Optiray-320 also demonstrated two phases, with half-times of 2.5 and 45 minutes. The IVC became less dense than liver within 5-8 minutes. Conclusion. [Dy]DTPA-dextran is water soluble and can be synthesized without intermolecular cross-linking to carry a high load of dysprosium. It provides blood pool enhancement characteristics with a long intravascular dwell time.

KW - Computed tomography (CT), contrast media

KW - Computed tomography (CT), vascular studies

KW - Dysprosium

UR - http://www.scopus.com/inward/record.url?scp=0036314856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036314856&partnerID=8YFLogxK

U2 - 10.1016/S1076-6332(03)80348-3

DO - 10.1016/S1076-6332(03)80348-3

M3 - Article

C2 - 12139092

AN - SCOPUS:0036314856

VL - 9

SP - 784

EP - 792

JO - Academic Radiology

JF - Academic Radiology

SN - 1076-6332

IS - 7

ER -